Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

NCT02998710 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices

Study Locations (11)

Other

  • Travere Investigational Site — Dublin
  • Travere Investigational Site — Doha

California

  • Travere Investigational Site - Virtual Site — Culver City

Colorado

  • Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) — Aurora

District of Columbia

  • Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) — Washington D.C.

Georgia

  • Travere Investigational Site — Atlanta

Indiana

  • Travere Investigational Site — Indianapolis

Massachusetts

  • Travere Investigational Site — Boston

Pennsylvania

  • Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) — Philadelphia

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2017-01
Est. Completion 2026-08

Sponsor

Travere Therapeutics

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02998710

The ClinicalTrials.gov registry entry for NCT02998710 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travere Therapeutics, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Homocystinuria Due to CBS Deficiency appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02998710 reports 11 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02998710 about?

NCT02998710 is a clinical study titled "Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)". The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices

What is the current status of trial NCT02998710?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2017-01. Estimated completion is 2026-08.

What conditions does trial NCT02998710 study?

This clinical trial studies the following conditions: Homocystinuria Due to CBS Deficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02998710?

This trial is sponsored by Travere Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02998710 being conducted?

This trial has 11 study locations across California, Colorado, District of Columbia, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial